Zannettino ACW - Search Results

1

GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice.

Friend N, Noll JE, Opperman KS, Clark KC, Mrozik KM, Vandyke K, Hewett DR, Zannettino ACW. Friend N, et al. Among authors: zannettino acw. PLoS One. 2020 Jan 29;15(1):e0228408. doi: 10.1371/journal.pone.0228408. eCollection 2020. PLoS One. 2020. PMID: 31995627 Free PMC article.

2

Heat shock protein-90 beta is expressed at the surface of multipotential mesenchymal precursor cells: generation of a novel monoclonal antibody, STRO-4, with specificity for mesenchymal precursor cells from human and ovine tissues.

Gronthos S, McCarty R, Mrozik K, Fitter S, Paton S, Menicanin D, Itescu S, Bartold PM, Xian C, Zannettino AC. Gronthos S, et al. Stem Cells Dev. 2009 Nov;18(9):1253-62. doi: 10.1089/scd.2008.0400. Stem Cells Dev. 2009. PMID: 19327008

3

Dysregulation of bone remodeling by imatinib mesylate.

Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino AC. Vandyke K, et al. Blood. 2010 Jan 28;115(4):766-74. doi: 10.1182/blood-2009-08-237404. Epub 2009 Nov 4. Blood. 2010. PMID: 19890095 Free article. Review.

4

Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells.

Martin SK, Diamond P, Williams SA, To LB, Peet DJ, Fujii N, Gronthos S, Harris AL, Zannettino AC. Martin SK, et al. Haematologica. 2010 May;95(5):776-84. doi: 10.3324/haematol.2009.015628. Epub 2009 Dec 16. Haematologica. 2010. PMID: 20015878 Free PMC article.

5

The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo.

Vandyke K, Dewar AL, Diamond P, Fitter S, Schultz CG, Sims NA, Zannettino AC. Vandyke K, et al. J Bone Miner Res. 2010 Aug;25(8):1759-70. doi: 10.1002/jbmr.85. J Bone Miner Res. 2010. PMID: 20225261 Free article.

6

Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients?

Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino AC. Fitter S, et al. J Clin Endocrinol Metab. 2010 Aug;95(8):3763-7. doi: 10.1210/jc.2010-0086. Epub 2010 May 13. J Clin Endocrinol Metab. 2010. PMID: 20466781 Clinical Trial.

7

Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion.

Fitter S, Vandyke K, Gronthos S, Zannettino AC. Fitter S, et al. J Mol Endocrinol. 2012 May 8;48(3):229-40. doi: 10.1530/JME-12-0003. Print 2012 Jun. J Mol Endocrinol. 2012. PMID: 22474082

8

Tug of war in the haematopoietic stem cell niche: do myeloma plasma cells compete for the HSC niche?

Noll JE, Williams SA, Purton LE, Zannettino AC. Noll JE, et al. Blood Cancer J. 2012 Sep 14;2(9):e91. doi: 10.1038/bcj.2012.38. Blood Cancer J. 2012. PMID: 22983434 Free PMC article.

9

Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects.

Vandyke K, Fitter S, Drew J, Fukumoto S, Schultz CG, Sims NA, Yeung DT, Hughes TP, Zannettino AC. Vandyke K, et al. J Clin Endocrinol Metab. 2013 Jan;98(1):67-76. doi: 10.1210/jc.2012-2426. Epub 2012 Nov 8. J Clin Endocrinol Metab. 2013. PMID: 23144472 Clinical Trial.

10

EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair.

Arthur A, Panagopoulos RA, Cooper L, Menicanin D, Parkinson IH, Codrington JD, Vandyke K, Zannettino AC, Koblar SA, Sims NA, Matsuo K, Gronthos S. Arthur A, et al. J Bone Miner Res. 2013 Apr;28(4):926-35. doi: 10.1002/jbmr.1821. J Bone Miner Res. 2013. PMID: 23165754 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

215 results

Search Page